IDEAYA Biosciences, Inc. focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.The company's lead product candidates include a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions.
